ValuEngine Upgrades Oxford Immunotec Global (OXFD) to Buy

ValuEngine upgraded shares of Oxford Immunotec Global (NASDAQ:OXFD) from a hold rating to a buy rating in a research report report published on Wednesday.

Several other research analysts have also issued reports on the stock. BidaskClub lowered shares of Oxford Immunotec Global from a sell rating to a strong sell rating in a research note on Friday, July 20th. Zacks Investment Research lowered shares of Oxford Immunotec Global from a hold rating to a sell rating in a research note on Friday, June 1st. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $17.80.

Shares of NASDAQ OXFD opened at $15.63 on Wednesday. The firm has a market cap of $408.99 million, a P/E ratio of -11.49 and a beta of -0.20. Oxford Immunotec Global has a 12-month low of $10.00 and a 12-month high of $17.41. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.86 and a current ratio of 5.39.

Oxford Immunotec Global (NASDAQ:OXFD) last issued its earnings results on Tuesday, July 31st. The company reported ($0.25) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.25). The business had revenue of $29.32 million for the quarter, compared to analyst estimates of $28.58 million. Oxford Immunotec Global had a negative net margin of 23.41% and a negative return on equity of 39.85%. Oxford Immunotec Global’s revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.74) earnings per share. equities research analysts predict that Oxford Immunotec Global will post -0.95 earnings per share for the current fiscal year.

In related news, CEO Peter Wrighton-Smith sold 40,000 shares of the firm’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $14.95, for a total transaction of $598,000.00. Following the transaction, the chief executive officer now directly owns 525,296 shares of the company’s stock, valued at $7,853,175.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $13.15, for a total transaction of $39,450.00. The disclosure for this sale can be found here. 6.61% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can bought a new position in shares of Oxford Immunotec Global during the second quarter valued at about $132,000. State Board of Administration of Florida Retirement System bought a new position in shares of Oxford Immunotec Global during the second quarter valued at about $140,000. Quantitative Systematic Strategies LLC bought a new position in shares of Oxford Immunotec Global during the first quarter valued at about $177,000. JPMorgan Chase & Co. lifted its position in shares of Oxford Immunotec Global by 258.0% during the first quarter. JPMorgan Chase & Co. now owns 19,554 shares of the company’s stock valued at $243,000 after purchasing an additional 14,092 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Oxford Immunotec Global by 84.7% during the second quarter. Renaissance Technologies LLC now owns 21,058 shares of the company’s stock valued at $271,000 after purchasing an additional 9,658 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Read More: Growth Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit